Centene Corporation (CNC)
59.47 USD +1.78 (+3.09%) Volume: 8.28M
Centene Corporation’s stock price stands at 59.47 USD, showcasing a positive surge of +3.09% in the current trading session with a robust trading volume of 8.28M. Despite the year-to-date percentage change recording a slight dip of -1.83%, the stock continues to exhibit a dynamic performance in the market.
Latest developments on Centene Corporation
Centene Corp (CNC) has seen its stock outperform competitors on a strong trading day, following its Q1 2025 earnings call which highlighted strong revenue growth and strategic wins. Despite Barclays reducing its price target for CNC to $84, analysts remain optimistic about the company’s future, with 4 projections forecasting positive outcomes. The Q1 earnings snapshot revealed a mixed outlook, leading to a reduction in price target, but investors are decoding Centene Corp‘s strategic SWOT insight to navigate through the fluctuations in the stock market today.
Centene Corporation on Smartkarma
Analysts at Baptista Research are bullish on Centene Corp, citing the company’s strong performance in its Medicare segment as a key driver for their optimism. The recent financial results for the fourth quarter of 2024 showed solid earnings power, with adjusted diluted earnings per share (EPS) of $0.80 and a full-year EPS of $7.17. This growth is attributed to robust performance across its business lines, including Medicare and Medicaid, and significant operational improvements.
In another report by Baptista Research, analysts highlight Centene Corporation’s operational efficiency and AI utilization as major drivers for their optimism. The company’s third-quarter financial results for 2024 exceeded expectations, with an adjusted diluted EPS of $1.62. This outperformance was partly due to realized tax benefits and accelerated income tax benefits. Despite ongoing challenges within its operations, analysts remain bullish on Centene Corp‘s prospects.
A look at Centene Corporation Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Centene Corporation, a multi-line managed care organization, shows a promising long-term outlook based on Smartkarma Smart Scores. With high scores in Value, Growth, and Momentum, the company is positioned well for future success. Centene’s strong value score indicates that it is currently undervalued in the market, presenting a potential opportunity for investors. Additionally, its impressive growth and momentum scores suggest that the company is experiencing positive trends and is likely to continue expanding in the future.
Despite a lower score in Dividend and Resilience, Centene Corp‘s overall outlook remains positive. The company’s focus on providing Medicaid and Medicaid-related programs, along with specialty services like behavioral health, nurse triage, and treatment compliance, positions it as a key player in the healthcare industry. With a solid foundation and strong growth potential, Centene Corp is poised for long-term success in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
